Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

Sponsor

Washington University School of Medicine (Other)

Overall Status

Recruiting

CT.gov ID

NCT05947643

Collaborator

(none)

240

Enrollment

Location

Arms

18.3

Anticipated Duration (Months)

13.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be asked to rinse their nose with a medication or placebo capsule dissolved in saltwater twice daily for 12 weeks and fill out surveys about smell before, during, and at the end of treatment.

This study will also be used to describe adverse effects related to intranasal theophylline irrigation.

Condition or Disease	Intervention/Treatment	Phase
COVID-19	Drug: theophylline Drug: Placebo	Phase 2

Detailed Description

COVID-related olfactory dysfunction (OD) is a major symptom of infection with SARS-COV-2, affecting up to 80% of those with COVID-19. While research on the pathogenesis is ongoing, a significant subset is expected to suffer from long-term OD. The investigators seek to test intranasal theophylline nasal irrigation as a potential therapeutic option for treatment of COVID-related OD lasting over 3 months.

Theophylline has been shown to improve outcomes in post-viral OD in pilot studies, and initial data suggests therapeutic benefit in patients with post-COVID OD with minimal systemic absorption.

The primary hypothesis is that theophylline irrigation will be more effective than placebo saline irrigation for COVID-19 related OD symptoms. The use of intranasal theophylline will have minimal adverse effects.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

240 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Intervention Model Description:

Single-site, double-blinded, placebo-controlled randomized clinical trial performed at a tertiary academic medical center.Single-site, double-blinded, placebo-controlled randomized clinical trial performed at a tertiary academic medical center.

Masking:

Double (Participant, Investigator)

Masking Description:

Double-blinded, meaning neither the subjects nor the investigators will be aware of the intervention received by any subject.

Primary Purpose:

Treatment

Official Title:

Smell in COVID-19 and Efficacy of Nasal Theophylline 3

Actual Study Start Date :

Nov 22, 2022

Anticipated Primary Completion Date :

Jun 1, 2024

Anticipated Study Completion Date :

Jun 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Theophylline Participants will dissolve the contents of the 400 mg theophylline capsules (experimental) into the sinus rinse bottle containing nasal saline.	Drug: theophylline capsules dissolved in intranasal irrigation
Placebo Comparator: Placebo Participant will dissolve the contents of the identical-appearing lactose capsules (control) into the sinus rinse bottle containing nasal saline.	Drug: Placebo identical-appearing lactose capsules dissolved in intranasal irrigation Other Names: inactive medicine

Arm

Intervention/Treatment

Experimental: Theophylline

Participants will dissolve the contents of the 400 mg theophylline capsules (experimental) into the sinus rinse bottle containing nasal saline.

Drug: theophylline

capsules dissolved in intranasal irrigation

Placebo Comparator: Placebo

Participant will dissolve the contents of the identical-appearing lactose capsules (control) into the sinus rinse bottle containing nasal saline.

Drug: Placebo

identical-appearing lactose capsules dissolved in intranasal irrigation

Other Names:

inactive medicine

Outcome Measures

Primary Outcome Measures

Clinical Global Impression Scale (CGI) [Week 6 and week 12 of treatment]
The CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC). The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). CGI scores range from 1 (very much improved) through to 7 (very much worse). We will measure the response rate defined as the number of participants self-reporting minimal change or larger in the Clinical Global Impression Scale (CGI) scale, divided by the number of participants in each group.

Secondary Outcome Measures

Olfactory Dysfunction Outcomes Rating (ODOR) [Week 6 and week 12 of treatment]
ODOR is a disease-specific questionnaire that assesses for physical, functional, and emotional limitations in participants with olfactory dysfunction of any etiology. The instrument contains 28 total items with each scored on a 5-point Likert scale from 0 to 4.
Assessment of adherence [Week 1-2 of treatment]
Number of irrigations completed over the prior 7 days out of a possible 14.
Assessment of blind [Week 1-2 of treatment]
Participants will be asked to guess whether they are in the theophylline or placebo arm of the study.
Adverse effects [Patients may report this information any time during 12 weeks of treatment. They are asked about this at weeks 3, 6, 9, and 12 of treatment.]
Patients will be asked to report any adverse effects they experience.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Participants will be recruited based on the following inclusion criteria:

males and females ages 18 to 75 years
located within or willing to travel to the state of Missouri or Illinois
Olfactory dysfunction that has persisted for >3 months following suspected COVID-19 infection
Baseline University of Pennsylvania Smell Identification Test (UPSIT) consistent with decreased olfactory function (<= 34 in women, <=33 in men). This test is a clinically validated 40-question forced-choice odor identification test where microencapsulated odorants on a strip are released by scratching.70 This will determine that patients have both subjectively and objectively diagnosed OD prior to undergoing treatment.
Ability to read, write, and understand English and have access to email.

Exclusion Criteria:

Individuals will not be allowed to participate in this study if they meet one or more of the following exclusion criteria:

History of olfactory dysfunction prior to COVID-19 infection
Any use of concomitant therapies specifically for the treatment of olfactory dysfunction
Use of or participation in previous trials of intranasal theophylline.
Known existence of nasal polyps, prior sinonasal, or anterior skull-based surgery
Dependence on theophylline for comorbid conditions such as asthma and chronic obstructive pulmonary disease (COPD)
History of an allergic reaction to theophylline or other methylxanthines
History of neurodegenerative disease (ie. Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia)
Pregnant or breastfeeding mothers.
Current use of medications with significant (≥40%) interactions with theophylline, which include cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine, interferon- alpha, lithium, mexiletine, phenytoin, propafenone, propranolol, tacrine, thiabendazole, ticlopidine, and troleandomycin.